Healio5d
Mepolizumab lowers repeat surgery risk for CRSwNP regardless of number of past surgeries
Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not ...
How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology
After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma ...
Pharmabiz6d
EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment
EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...
EMA to review GSK’s Nucala for COPD treatment expansion
GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant ...
Devdiscourse7d
Global Health Concerns: Rising TB, Bird Flu in Mammals, and Pharmaceutical Updates
Recent health news highlights a 10% rise in child TB infections in Europe, detected mammal bird flu cases, and economic ...
Devdiscourse7d
Global Health Headlines: TB, Bird Flu, and Big Pharma Moves
Current health news highlights a 10% rise in child TB infections in Europe, a new drug review by European regulators, the ...
Zacks Investment Research on MSN8d
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD
GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking ...
GSK application to expand use of Nucala to COPD accepted for review by EMA
GSK (GSK) plc announced that the European Medicines Agency has accepted for review its application to expand the use of Nucala, a monoclonal ...
EMA accepts GSK's application to expand Nucala use
GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of ‘Nucala’, or ...
Plus500 buys Mehta Equities, EMA accepts GSK's application to extend use of Nucala
London open The FTSE 100 is expected to open 28 points higher on Monday, having closed down 0.63% on Friday at 8,646.79.
GSK says European regulator reviewing expanded use of asthma drug Nucala
GSK on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker's ...
GSK has application to expand use of mepolizumab accepted by EMA
(Alliance News) - GSK PLC on Monday said it has had an application to expand the use of mepolizumab for the treatment of chronic obstructive pulmonary disease accepted for review by the European ...